BioSpecifics Technologies Corp
BioSpecifics Technologies — Investor Presentation (September 2015)
23 slides from BioSpecifics Technologies's investor presentation, Sep 3, 2015
Slide 1: Innovators in the development & commercialization of injectable collagenase
Innovators in the development & commercialization of INJECTABLE COLLAGENASE On BioSpecifics September 2015
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding
Slide 3: BioSpecifics is a profitable, commercial-stage biopharma company
BioSpecifics is a profitable, commercial-stage biopharma company receiving increasing revenues from sales of collagenase clostridium histolyticum or CCH (XIAFLEX®) by partner Endo with future revenue growth opportunities emerging from commitment to clinical development of new potential indications f
Slide 4: Unlocking Vast Potential of CCH
Unlocking Vast Potential of CCH First-in-class, minimally invasive nonsurgical treatment for conditions caused by collagen accumulation with limited current treatment options BioSpecifics has positive clinical results in 12 indications: Dupuytren’s contracture* Frozen shoulder Scarred tendons Peyron
Slide 5: XIAFLEX for Dupuytren's Contracture
XIAFLEX for Dupuytren’s Contracture First, Effective Non-Surgical Treatment Option - Collagen cord in hand causing one or more fingers to contract toward Definition & Key the palm Complications Limits range of motion and impairs quality of life Affects up to 7% of adults in the U.S. Pre- treatment:
Slide 6: Commercial Highlights for DC
Commercial Highlights for DC ~6,200 vials were shipped April 1, 2015 through June 30, 2015 Compared to 5,092 in 2Q14 Updated U.S. label including recurrence and retreatment data approved in May 2015 MULTICORD U.S. label expansion approved in October 2014 Treatment of up to two contracture joints in
Slide 7: XIAFLEX for Peyronie's Disease
XIAFLEX for Peyronie’s Disease First, Effective Non-Surgical Treatment Option Inelastic collagen causing penile curvature; penis can bend at 90° angle during erection in severe cases Associated with increased pain, painful erections, palpable Definition & plaque, penile deformity and erectile dysfun
Slide 8: Commercial Highlights for PD
Commercial Highlights for PD ~6,900 vials were shipped April 1, 2015 through June 30, 2015 Compared to 2,752 in 2Q14 Continued traction with certified physicians and new patients in Peyronie’s disease As of June 30, 2015 there were ~2,100 certified physicians and “9,800 cumulative patients enrolled
Slide 9: XIAFLEX Pipeline Programs
XIAFLEX Pipeline Programs Future Revenue-Generating Opportunities Frozen Shoulder Phase 2b to initiate by end of 2015 Syndrome Cellulite Phase 2b to initiate by end of 2015 *Human Lipoma Phase 2 top-line results 1H16 KecmilitS Endo has license for further development Lipoma *Uterine Positive Soa ta
Slide 10: CCH for Frozen Shoulder Syndrome
CCH for Frozen Shoulder Syndrome Potential to be Only FDA Approved Nonsurgical Therapy Definition & Complications Inflammation and thickening of shoulder capsule due to collagen Limits range of motion of shoulder Common available treatment options are often painful and can Potential to be F : requir
Slide 11: Phase 2b Study of CCH in Frozen Shoulder
Phase 2b Study of CCH in Frozen Shoulder Study Design Double-blind, placebo-controlled study evaluating safety and .. . efficacy in Stage 2 (frozen stage) unilateral idiopathic frozen shoulder Objective & Rationale Phase 2b study based on positive, statistically significant results in Phase 2a study
Slide 12: Phase 2b Study Results of CCH in FSS
Phase 2b Study Results of CCH in FSS Phase 2a Results Strong, similar drug effect for key measures 607 including forward flexion, shoulder abduction, external and internal rotation across both Phase 2a and Phase 2b trials Similar CCH patient improvement in pain seen across both trials Degree Improve
Slide 13: CCH for Cellulite
CCH for Cellulite Phase 2b Trial to Initiate by End of 2015 Definition Significant Market Opportunity as First Nonsurgical Therapy Positive Top-line Results Reported from Phase 2a Study in3Q14 Source: Endo International, ple Skin dimpling as a result of collagen fibrous septae, occurring mainly on t
Slide 14: CCH for Cellulite
CCH for Cellulite Positive Top-line Data from Phase 2a Study Top-line Data from Phase 2a Study Mid and high level CCH doses demonstrated statistically significant improvement in cellulite across all endpoints 68% of mid and high dose groups reported being “Satisfied” or “Very Satisfied” with treatme
Slide 15: CCH for Human Lipomas
CCH for Human Lipomas Phase 2 Opt-In Study Managed by BioSpecifics Encapsulated deposits of benign fatty tumors; detected as bulges RrsalietSLo under the skin Potential to be No FDA-approved pharmaceutical therapies available Only Approved ; ; : — Nonsurgical Therapy Surgery not practical for patien
Slide 16: Positive Phase Clinical Trial Results
Positive Phase 2 Clinical Trial Results Reported in January 2014 Open label, dose escalation Phase 2 trial: Statistically significant (p<0.0001) reduction in primary endpoint of visible surface area of lipoma as measured by caliper, combining all patients Patients in highest dose group (75% of comme
Slide 17: CCH for Lipomas in Canines
CCH for Lipomas in Canines Lipomas can seriously restrict motion in older dogs Key Complications Surgery can be risky due to the use of general anesthesia - especially for older dogs Potential to be 1.7M dogs affected in the U.S. annually Only Approved Based ona survey of 77 participants, an average
Slide 18: CCH for Uterine Fibroids
CCH for Uterine Fibroids Endo Encouraged by Results Reported to Date =) rose Definition & Fan, eeErare zt fertility, S asso is il Key c licati miscarriage, heavy menstrual H a= ey Complication? bleeding and frequent urination [3008 jo | Potential to be Primary indication for “0m 025 050 400 200 Nons
Slide 19: Endo Partnership for Development and Commercialization of CCH
Endo Partnership for Development and Commercialization of CCH $62.9M received in licensing, sublicensing, milestone, COGS, and >$62.9M Received royalty payments as of June 30, 2015 to Date To receive a % of $20M milestone payment due to Endo upon first commercial sale in Japan Low double digit royal
Slide 20: Corporate Highlights
Corporate Highlights Vast opportunity for growth in revenues from XIAFLEX sales and approval of CCH in new indications Strong IP portfolio Long-term patent protection for injectable collagenase: » Dupuytren’s Contracture: XIAFLEX has Drug product composition patent until 2028 and Biologic Exclusivit
Slide 21: Consistently Profitable Annually
Consistently Profitable Annually Financial Highlights (unaudited) For the six months ended 06/30/15 06/30/14 Cash and equivalents, and investments $29,230,046 $16,633,708 Income Statement Revenues $10,321,429 $5,399,657 Other income 36,835 29,600 Costs and expenses (4,094,588) (3,405,855) Provision
Slide 22: Anticipated Upcoming Milestones
Anticipated Upcoming Milestones Upcoming Milestones * foe O Phase 2 placebo-controlled opt-in trial top-line results in 1H16 *Uterine O Refi devel Ei Fibroids efining development plan Peyronie’s Recess Q) Building sales momentum in the EU Dupu' n’s Peas O Commercial launch in Japan on September 16,
Slide 23: Innovators in the development & commercialization of injectable collagenase
\ a? Innovators in the development & commercialization of ‘INJECTABLE COLLAGENASE ee . BioSpecifics September 2015
Biospecifics Technologies — Investor Presentation (September 2015) on 6ix